United Therapeutics (UTHR) Accounts Payables (2009 - 2026)

United Therapeutics has disclosed Accounts Payables across 18 years of filings, most recently posting $497.8 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 15.23% year-over-year to $497.8 million; the TTM figure through Jun 2026 stood at $497.8 million (up 15.23% YoY), while the FY2025 annual figure was $488.0 million, up 41.65% from the prior year.
• Accounts Payables came in at $497.8 million for Q2 2026 at United Therapeutics, roughly flat from $498.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $498.3 million in Q1 2026 to a low of $166.4 million in Q1 2022.
• Average Accounts Payables over 5 years is $337.0 million, with a median of $329.3 million recorded in 2023.
• Year-over-year, Accounts Payables advanced 0.85% in 2022 and jumped 51.48% in 2023.
• Over 5 years, Accounts Payables stood at $229.9 million in 2022, then advanced by 29.62% to $298.0 million in 2023, then climbed by 15.6% to $344.5 million in 2024, then jumped by 41.65% to $488.0 million in 2025, then climbed by 2.01% to $497.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $497.8 million in Q2 2026, $498.3 million in Q1 2026, and $488.0 million in Q4 2025.